Patents Assigned to Seattle Project Corp.
  • Alphavirus neoantigen vectors and interferon inhibitors
    Patent number: 12653883
    Abstract: Disclosed herein are vectors that include alphavirus-based expression platforms. Also disclosed are methods associated with the alphavirus-based expression platforms and co-administration of an inhibitor of Type I interferon signaling.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: June 16, 2026
    Assignee: Seattle Project Corp.
    Inventors: Karin Jooss, Amy Rachel Rappaport, Leonid Gitlin
  • Infectious disease antigens and vaccines
    Patent number: 12616746
    Abstract: Disclosed herein are compositions that include antigen-encoding nucleic acid sequences and/or antigen peptides. Also disclosed are nucleotides, cells, and methods associated with the compositions including their use as vaccines, including vectors and methods for a heterologous prime/boost vaccination strategy.
    Type: Grant
    Filed: October 3, 2022
    Date of Patent: May 5, 2026
    Assignee: Seattle Project Corp.
    Inventors: Andrew Ferguson, Raphael Rousseau, Roman Yelensky, James Xin Sun, Matthew Joseph Davis, Karin Jooss, Amy Rachel Rappaport, Ciaran Daniel Scallan, Leonid Gitlin, Christine Denise Palmer